CHONGQING, China, Sept. 23, 2025 /PRNewswire/ — From August 20 to 24, the VCT 2025: China Stage 2, hosted by TJ Sports and organized by Hero Esports, successfully concluded at the Chongqing Science Hall.

The event drew over 20,000 VALORANT fans to the venue. The stage boasted a panoramic, wrap-around layout featuring a total of 12 massive screens, which provided a seamless 360-degree viewing experience. No matter where fans were seated, attendees could follow every critical moment of the matches in real time.

During the finals, the band Life Awaits electrified the crowd with a powerful performance of the VCT CN theme song You Call Me Reckless. Amid roaring cheers, Bilibili Gaming (BLG) and Dragon Ranger Gaming (DRG) took the stage to battle for the championship.

BLG defeated DRG with a decisive 3-1 score, claiming the 2025 VCT CN annual championship and securing their first-ever league title. Player BLG.whzy was awarded the FMVP.

Cross-Community Fun: VALORANT 2nd Anniversary Carnival Turns Up the Heat

Beyond the matches at the Science Hall, the VALORANT 2nd Anniversary Carnival offered a diverse array of exciting activities. From music parties and community challenges to a stunning drone light show, VALORANT fans joined together to set Chongqing ablaze with energy.

The carnival brought together streamers, pro players, and cross-industry influencers, blending esports with basketball, rap, street dance, and other trendy elements to create a fully immersive experience. Surprise appearances by famous Chinese rappers Lan Lao and GALI, as well as comedian Fu Hang, added to the excitement. Basketball star Guo Ailun also made a special appearance at the “Aim Training Camp.”

An exclusive EDM party for VALORANT fans kicked into high gear. Six renowned DJs, including ISOxo and RL Grime, gathered in Chongqing, delivering explosive beats that defined the ultimate live experience. Meanwhile, on the evening of the 23rd, a breathtaking light show performed by 500 drones illuminated the night sky, showcasing VALORANT’s iconic elements.

According to statistics, the carnival attracted over 1.5 million offline attendees, while the global online and offline viewership reached over 100 million.

Onward to Paris: VCT CN Teams Ready for Champions

As the event drew to a close, rapper GAI took the stage, performing his hit song “Chaotianmen” to ignite the crowd and energize the CN teams preparing for their upcoming matches

BLG, DRG, EDG, and XLG were officially unveiled at the send-off ceremony. These four teams will head to Paris in September to represent the CN region at the VALORANT Champions 2025. With new battles on the horizon, they are ready to face the world’s best with courage and determination—giving their all in the pursuit of victory!

About Hero Esports

Founded in 2016, Hero Esports is the biggest esports company in Asia, producing more than 7,000 matches every year that captivate an online fan base of over 800 million. Headquartered in Shanghai and employing more than 1,100 employees, Hero Esports boasts a global presence encompassing 12 office locations and eight top-tier esports arenas. Hero Esports offers a comprehensive suite of esports services, including tournament organization, marketing solutions, community development, and more.

New model democratizes access to financial research, widening use of exclusive financial data and workflows on Orbit Insight

LONDON, Sept. 23, 2025 /PRNewswire/ — Orbit Financial Technology today announced a new monthly membership system for Orbit Insight, its flagship research and analysis platform already used by leading asset managers and hedge funds. The change opens access to smaller firms, boutique funds, and independent researchers, giving them the same institutional-grade tools trusted by global investment houses.

Orbit Insight combines Orbit’s exclusive financial data with advanced AI infrastructure, including Retrieval-Augmented Generation (RAG) technology, to help investors screen tens of thousands of companies at once and conduct reliable multi-document analysis. The new membership model, called Orbit Flex, increases access to this capability, removing cost and access barriers and allowing a much broader audience to harness AI-driven insights.

Both research teams and individual investors have traditionally faced limits on the volume of data they can process, forcing painful choices around coverage. Orbit’s AI infrastructure enables users to screen tens of thousands of companies simultaneously, powered by Retrieval-Augmented Generation (RAG) technology for reliable multi-document analysis. In addition to Orbit’s exclusive data and analytics, users can import their own data into the Orbit environment.

Orbit integrates into leading large language models, including Claude, Copilot and ChatGPT.

Da Wei, Founder and CEO of Orbit Financial Technology, said: “The true magic of large language models is in unlocking previously impossible workflows. With the right data and our infrastructure, specialist institutional and sophisticated retail investors can tackle any research challenge without custom training. Democratizing access has also been a core tenet of Orbit. That’s why I’m thrilled that, after a decade of development, we can now make this advanced capability accessible to everyone”.

Unlike traditional data vendors charging blanket licensing fees, Orbit’s transparent credit-based system ensures users pay only for what they use. The platform also includes an “Agent marketplace”, allowing users to deploy AI agents tailored to their investment strategies. Popular agents include Filings Insight Extractor, Portfolio News Tracker and Data Transformer, as well as sustainability agents such as an Anti-greenwashing monitor.

Orbit has built one of the market’s most comprehensive financial data infrastructures. The platform processes over 70 million documents annually across 150,000+ companies in 80 countries, delivering unmatched market intelligence and regulatory insights. Get started with a complementary trial at orbitfin.ai/flex.

About Orbit

Orbit is a sophisticated AI-powered financial services platform designed to empower informed, data-driven decision-making. Founded in 2015, Orbit processes over 70 million documents annually across 150,000+ companies in 80 countries, delivering unmatched market intelligence and regulatory insights. Our platform combines comprehensive data coverage with advanced AI capabilities to transform unstructured data into actionable intelligence for asset managers, hedge funds, data vendors, exchanges, and software platforms. For more information, visit orbitfin.ai.

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ — The 2025 European Society for Medical Oncology (ESMO) Congress will take place in Berlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”, HKEX: 6990) will present results from multiple clinical studies at the congress, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT), HER2 ADC A166 (trastuzumab botidotin), and CLDN18.2 ADC SKB315. Among these, two Phase III clinical studies of sac-TMT were selected for the Latest Breakthrough Abstracts (LBA) and presented as oral reports, including one featured in the Presidential Symposium; one Phase III clinical study of A166 was selected for LBA and presented as oral report.

Abstract titles of these studies have been published on the official website of ESMO. The study results to be presented include:

Title: Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study
Presentation Type: Presidential Symposium 
Presentation #: LBA5
Date and Lecture Time: October 19, 4：52 PM to 5:04 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) vs investigator’s choice of chemotherapy (ICC) in previously treated locally advanced or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): results from the randomized, multi-center phase 3 OptiTROP-Breast02 study
Presentation Type: Proffered Paper
presentation #: LBA23
Date and Lecture Time: October 18, 10:45 AM to 10:55 AM local time

Title: Trastuzumab botidotin vs trastuzumab emtansine (T-DM1) in HER2-positive unresectable or metastatic breast cancer: results from a randomized phase 3 study
Presentation Type: Proffered Paper 
presentation #: LBA24
Date and Lecture Time: October 18, 10:55 AM to 11:05AM local time

Title: SKB315, a novel Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors including gastric/ gastroesophageal junction cancer (GC/GEJC): a phase 1 study
Presentation Type: Poster
Presentation #: 2139P
Date and Session Time: October 19, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) in Participants (pts) with Previously Treated, Advanced KRAS-Mutant NSCLC: Results from Cohort 5d of the SKB264-II-08 Study
Presentation Type: Poster
Presentation #: 1945P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) + pembrolizumab^[1] (pembro) for treatment-naïve advanced PD-L1 positive NSCLC: results from the Phase 2 MK-2870-003/SKB264-II-04 study
Presentation Type: Poster
Presentation #: 1949P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (sac-TMT) + Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from Phase 2 MK-2870-002/SKB264-II-06 Study
Presentation Type: Poster
Presentation #: 2421P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Sacituzumab tirumotecan (Sac-TMT) Monotherapy in Advanced/Metastatic Endometrial Carcinoma (EC): Results from a Phase 1/2 Study (MK-2870-001/KL264-01)
Presentation Type: Poster
Presentation #: 1111P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

Title: Efficacy and Safety of sacituzumab tirumotecan (Sac-TMT) Monotherapy in Advanced/Metastatic Cervical Cancer: Results from a Phase 1/2 Study (MK-2870-001/KL264-01)
Presentation Type: Poster
Presentation #: 1168P
Date and Session Time: October 18, 9:00 AM to 5:00 PM local time

About sac-TMT 

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).

To date, 2 indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting), EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the Center for Drug Evaluation of NMPA, and were included in the priority review and approval process. As of today, the Company has initiated 9 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Trastuzumab Botidotin (A166)

Trastuzumab botidotin is a differentiated HER2 ADC in new drug application (NDA) registration stage to treat advanced HER2+ solid tumors. As an innovative HER2 ADC developed by the Company, it conjugates a novel, MMAF derivative (a highly cytotoxic tubulin inhibitor, Duo-5) via a stable, enzyme-cleavable linker to a HER2 monoclonal antibody with a DAR of 2. Trastuzumab botidotin specifically binds to HER2 on the surface of tumor cells and is internalized by tumor cells, releasing the toxin molecule Duo-5 inside the cell. Duo-5 induces tumor cell cycle arrest in the G2/M phase, leading to tumor cell apoptosis. After targeting HER2, trastuzumab botidotin can also inhibit the HER2 signaling pathway; it has antibody-dependent cell-mediated cytotoxicity (ADCC) activity.

Based on the results of a randomized, controlled, open-label Phase III study, the New Drug Application (NDA) for trastuzumab botidotin was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in January 2025 for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA. At a pre-specified interim analysis, trastuzumab botidotin monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) as assessed by the Blinded Independent Central Review (BICR) compared with T-DM1.

Currently, Kelun-Biotech has initiated an open, multi-center Phase II clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase inhibitor ADC.

About SKB315

SKB315 is a novel CLDN18.2 ADC targeting advanced solid tumors configured with a proprietary, in-house developed humanized CLDN18.2 mAb and a differentiated payload-linker design. Currently, Kelun-Biotech has initiated the exploration in combination with immunotherapy for gastric/gastroesophageal junction cancer (GC/GEJC) while advancing monotherapy studies for tumors expressing CLDN18.2, such as GC/GEJC and pancreatic cancer.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 2 projects are in the NDA stage and more than 10 projects are in the clinical stage. The company has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 1 ADC project approved for marketing,1 ADC project in NDA stage and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.

LONDON, Sept. 23, 2025 /PRNewswire/ — Wahed, the world’s leading Islamic fintech welcomes Arnaut Danjuma, Zakaria Aboukhlal and Yunus Musah as shareholders and global ambassadors of Wahed.

Prominent footballers, Arnaut Danjuma, Zakaria Aboukhlal and Yunus Musah Become Shareholders in Wahed

Wahed has already built a unique ambassador family that brings together global sports icons such as Khabib Nurmagomedov and Paul Pogba representing the worlds of sport, faith, and influence. Today, Wahed expands this roster further, with three more internationally recognized footballers who embody values-driven success.

Arnaut, a professional footballer for Valencia and Netherlands noted: As an athlete, I’ve been blessed with a career that demands discipline, focus, and the right choices. I believe those same principles should guide the way I handle my finances.

Zakaria, who plays professionally for Torino and Morocco said: ‘I invested with Wahed because it reflects my values. Staying away from riba, choosing ethical finance, and thinking long term. For me, it’s not just about making money, it’s about doing things the right way.’

Yunus, a US Men’s National Team footballer and midfielder for Atalanta (on loan from AC Milan) commented: ‘Wahed gives us the opportunity to invest our capital and be assured that we are not involved in interest based revenue which is an important part of what we do.’

On welcoming them to Wahed, Mohsin Siddiqui, Chief Executive Officer noted: ‘Wahed was built on the principle of democraticising access to financial services. That we have garnered such support, from some of the most influential athletes in the world, is a testament to the vision of revolutionising how faith aligned investors can interact with the financial system.’

About Wahed

Wahed is a global Islamic fintech company committed to democratizing access to ethical investments. Licensed in more than 10 countries, Wahed combines cutting-edge financial technology with Shariah principles to deliver innovative products that align with both faith and values. With over 450,000 clients globally and more than $1 billion in assets under management across its entities, Wahed is pioneering a new era of Islamic finance.